Selling, general, and administration (SG&A) expenses for the quarter totalled $74 million and 23% of revenues compared to $61 million and 24% last year. The increase reflects the addition of MD, and SG&A in the other businesses was level with last year.

We spent $21 million on R&D activities in the third quarter this year and expensed $9 million, compared to spending of $13 million last year, of which we expensed $5 million. The majority of the increase in R&D spending comes from the additional spending in our new MD business.

Consolidated depreciation and amortization expense increased $12 million compared to the third quarter of last year. In the third quarter of 2007, we amortized $8 million of intangible assets acquired as part of the MD transaction. Capital expenditures for the quarter were $28 million and included $13 million for a property acquisition related to the expansion of our early-stage business in Phoenix, Arizona.

Income from continuing operations for the quarter was $8 million, reflecting these strong results from our businesses and was up 167% compared to $3 million reported for continuing operations last year. Excluding adjusting items, income from continuing operations was $17 million or $0.14 per share.

The loss from discontinued operations of $1 million for the third quarter this year reflects costs associated with the sale of our Canadian diagnostics businesses. Income from discontinued operations of $16 million for 2006 reflects the operating results of our Canadian diagnostics businesses for that period.

Earnings per share from continuing operations were $0.07 for the quarter, compared to $0.02 in 2006. Adjusted earnings per share from continuing operations for the quarter were $0.14 compared to $0.01 earned in the same period last year. Earnings per share from discontinued operations were a loss of $0.01 compared to income of $0.11 last year. Adjusted earnings per share
'/>"/>

• AIDS/HIV
• Bioinformatics
• Biotechnology
• Biochemistry
• Cancer
• Cell Biology
• Developmental Biology
• Ecology
• Environment
• Evolution
• Food Technology
• Gene
• Genetics
• Genomics
• Health/Medicine
• Immunology
• Microarray
• Microbiology
• Molecular
• Marine Biology
• Nanobiotechnology
• Neurobiology
• Plant Sciences
• Stem Cell
• Systems Biology
• Virus
• Women Health

• Abortion
• Aches
• ADHD
• Addiction
• Alcohol
• Allergy
• Alternative Medicine
• Alzheimer's Dementia
• Anxiety/Stress
• Arthritis
• Autism
• Bacteria
• Blood
• Bird Flu/Avian Flu
• Bones
• Breast Cancer
• Cancer
• Cardiovascular
• Cervical Cancer
• Chikungunya
• Cholesterol
• Clinical Trials
• Colorectal Cancer
• Conferences
• Crohn's
• Cystic Fibrosis
• Dengue
• Dentistry
• Depression
• Diabetes
• Drug
• Eating Disorders
• Education
• Epilepsy
• Erectile Dysfunction
• Eye Health/Blindness
• Fertility
• Flu/Cold
• GastroIntestinal
• Genetics
• Gout
• Headache/Migraine
• Hearing/Deafness
• HIV/AIDS
• Huntington's Disease
• Hypertension
• Immune System/Vaccines
• Insurance
• Infectious Diseases
• Irritable-Bowel Syndrome
• Internet
• Leukemia
• Lifestyle
• Liver Disease/Hepatitis
• Lung Cancer
• Lupus
• Mad Cow Disease
• Medical Devices
• Medical Students/Training
• Medicare/Medicaid
• Medico
• Men's health
• Mental Health
• MRI/Ultrasound
• MRSA/Drug Resistance
• Multiple Sclerosis
• Muscular Dystrophy
• Neurology
• Nursing
• Nutrition/Diet
• Obesity/Weight Loss
• Pain/Anesthetics
• Parkinson's Disease
• Pediatrics/Children's Health
• Pharma/Biotech Industry
• Pharmacy/Pharmacists
• Pregnancy
• Premature
• Prostate
• Psychology/Psychiatry
• Rehabilitation
• Respiratory/Asthma
• SARS
• Schizophrenia
• Seniors/Aging
• Sexual Health
• Sleep/Sleep Disorders
• Smoking
• Statins
• Stem Cell Research
• Stroke
• Surgery
• Transplants/Organ Donations
• Viruses
• Water - Air Quality
• Women's Health